First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality performed numerically better than the active comparator on key secondary endpoints of the CHALLENGE-MIG trial The CHALLENGE-MIG study demonstrates Lilly’s commitment to migraine research and results underscore that people living … Read more